First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized TrialCesare Gridelli, Francesco Perrone, Fortunato Ciardiello et al.|Journal of Clinical Oncology|2012Cited by 234
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trialRafael Rosell, Rolf A. Stahel, Urania Dafni et al.|The Lancet Respiratory Medicine|2017Cited by 184
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO FoundationSara Lonardi, M. Frisinghelli, Cosimo Rasola et al.|Journal of Clinical Oncology|2023Cited by 41
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung CancerMassimo Di Maïo, Cesare Gridelli, Natasha B. Leighl et al.|Journal of Thoracic Oncology|2012Cited by 26
Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trialsMassimo Di Maïo, Cesare Gridelli, Elena Piazza et al.|Lung Cancer|2012Cited by 22